PledPharma AB, a subsidiary of Accelerator rearranged its board and recruited two members with substantially know-how within the pharmaceutical industry and research. Louis Ignarro, awarded with the 1998 Nobel Prize in Physiology or Medicine and Sven Erik Sjöstrand, inventor of Losec/ Prilosec .
Prof. Sven Erik Sjöstrand has en extensive background within Astra’s gastrointestinal research and was project manager and inventor of Astras blockbuster drug Losec (Prilosec).
Louis Ignarro, University of California School of medicine in Los Angeles, was awarded with the 1998 Nobel Prize in Physiology or Medicine for his discovery concerning nitric oxide as a signalling molecule in the cardiovascular system.
– Besides a quality assurance, the recruitment implicates a competence and network reinforcement, says Andreas Bunge, CEO of Accelerator Nordic AB (principal owner of PledPharma AB).
For more information see www.pledpharma.se
PledPharma AB develops new pharmaceutical applications based on a clinically approved PLEDderivative, PP-095, with an initial candidate for oncology entering Clinical Phase II trials in 2008. PledPharma’s core technology is an omnipotent catalytic antioxidant that has characteristics that protect healthy cells during cancer treatment with chemotherapy and/or radiation. When used as an adjunct treatment, it has the potential to improve both clinical outcomes and patient well-being. In addition to cancer treatment, catalytic antioxidants have a wide range of potential indications, e.g., myocardial infarction, stroke and neurodegenerative diseases.